Rule 2, Drugs (Prices Control) Order, 2013: Definitions
Drugs (Prices Control) Order, 2013 - Rule 2
Text of rule 2
Definitions
2. Definitions.– (1) In this Order, unless the context otherwise
requires,–
(a) “Act” means the Essential Commodity Act, 1955 (10 of 1955);
(b) "active pharmaceutical ingredients or bulk drug" means
any pharmaceutical, chemical, biological or plant product including
its salts, esters, isomers, analogues and derivatives, conforming to
standards specified in the Drugs and Cosmetics Act, 1940 (23 of
1940) and which is used as such or as an ingredient in any
formulation;
(c) “brand” means a name, term, design, symbol, trademark or any
other feature that identifies one seller’s drug as distinct from those
of other sellers;
(d) "ceiling price" means a price fixed by the Government for
Scheduled formulations in accordance with the provisions of this
Order;
(e) "dealer" means a person carrying on the business of purchase or
sale of drugs, whether as a wholesaler or retailer and includes his
agent;
(f) "distributor" means a person engaged in the work of distribution
of drugs and includes an agent or a stockist for stocking drugs for
sale to a dealer;
(g) “existing manufacturer” means manufacturer existing on the
date of publication of this order in the Official Gazette.
(h) "Form" means a form specified in the Second Schedule;
(i) "formulation" means a medicine processed out of or containing
one or more drugs with or without use of any pharmaceutical aids,
for internal or external use for or in the diagnosis, treatment,
mitigation or prevention of disease and, but shall not include –
(i) any medicine included in any bonafide Ayurvedic (including
Sidha) or Unani (Tibb) systems of medicines;
THE DRUGS (PRICES CONTROL)
ORDER, 2013
(Notified by SO 1221 (E) dated 15.05.2013 and as amended
up to vide SO 1192(E) dated 22-03-2016)
In exercise of the powers conferred by section 3 of the Essential
Commodities Act, 1955, (10 of 1955), and supersession of the Drug
(Prices Control) Order, 1995, except as respect to things done or
omitted to be done before such supersession, the Central
Government hereby makes the following Order, namely:-
1. Short title and commencement.-— (1) This Order may be called
the Drugs (Prices Control) Order, 2013.
(2) It shall come into force on the date of its publication in the
Official Gazette.
2. Definitions.— (1) In this Order, unless the context otherwise
requires,-
(a) “Act” means the Essential Commodity Act, 1955 (10 of 1955);
(b) "active pharmaceutical ingredients or bulk drug" means
any pharmaceutical, chemical, biological or plant product including
its salts, esters, isomers, analogues and derivatives, conforming to
standards specified in the Drugs and Cosmetics Act, 1940 (23 of
1940) and which is used as such or as an ingredient in any
formulation;
(c) “brand” means a name, term, design, symbol, trademark or any
other feature that identifies one seller’s drug as distinct from those
of other sellers;
(d) "ceiling price" means a price fixed by the Government for
Scheduled formulations in accordance with the provisions of this
Order;
(e) "dealer" means a person carrying on the business of purchase or
sale of drugs, whether as a wholesaler or retailer and includes his
agent;
(f) "distributor" means a person engaged in the work of distribution
of drugs and includes an agent or a stockist for stocking drugs for
sale to a dealer;
(g) “existing manufacturer” means manufacturer existing on the
date of publication of this order in the Official Gazette.
(h) "Form" means a form specified in the Second Schedule;
(i) "formulation" means a medicine processed out of or containing
one or more drugs with or without use of any pharmaceutical aids,
for internal or external use for or in the diagnosis, treatment,
mitigation or prevention of disease and, but shall not include —
(i) any medicine included in any bonafide Ayurvedic (including
Sidha) or Unani (Tibb) systems of medicines;
(ii) any medicine included in the Homeopathic system of medicine;
and
(iii) any substance to which the provisions of the Drugs and
Cosmetics Act, 1940 (23 of 1940) do not apply;
(j) “generic version of a medicine” means a formulation sold in
pharmacopeial name or the name of the active pharmaceutical
ingredient contained in the formulation, without any brand name;
(k) "Government" means the Central Government;
(l) "import" with its grammatical variations and cognate expressions
means bringing a drug into India from a place outside India for its
sale;
(m) “local taxes” means any tax or levy (except excise or import
duty included in retail price) paid or payable to the Government or
the State Government or any local body under any law for the time
being in force by the manufacturer or his agent or dealer;
[(n) "manufacturer" for the purpose of this Order means any
person who manufactures or imports or markets drugs for
distribution or sale in the country; ]1
(o) “market share” means the ratio of domestic sales value (on the
basis of moving annual turnover) of a brand or a generic version of a
medicine and the sum of total domestic sales value of the all brands
and generic versions of that medicine sold in the domestic market
having same strength and dosage form;
(p) “margin to retailer” for the purposes of this Order shall mean
a percentage of price to retailer;
(q) “market based data” means the data of sales related to a drug
collected or obtained by the Government as deemed fit, from time to
time;
(r) “maximum retail price” means the ceiling price or the retail
price plus local taxes and duties as applicable, at which the drug
shall be sold to the ultimate consumer and where such price is
mentioned on the pack;
(s) “moving annual turnover” in a particular month means
cumulative sales value for twelve months in domestic market, where
the sales value of that month is added and the corresponding sales
of the same month in the previous year are subtracted;
(t) “National List of Essential Medicines” means National List of
Essential Medicines, 2011 published by the Ministry of Health and
Family Welfare as updated or revised from time to time and included
in the first schedule of this order by the Government through a
notification in the Official Gazette;
(u) “new drug” for the purposes of this Order shall mean a
formulation launched by an existing manufacturer of a drug of
specified dosages and strengths as listed in the National List of
Essential Medicines by combining the drug with another drug either
listed or not listed in the National List of Essential Medicines or a
formulation launched by changing the strength or dosages or both of
1 Substituted vide GSR 1233 (E), w.e.f. 08-05-2015
(ii) any medicine included in the Homeopathic system of medicine;
and
(iii) any substance to which the provisions of the Drugs and
Cosmetics Act, 1940 (23 of 1940) do not apply;
(j) “generic version of a medicine” means a formulation sold in
pharmacopeial name or the name of the active pharmaceutical
ingredient contained in the formulation, without any brand name;
(k) "Government" means the Central Government;
(1) "import" with its grammatical variations and cognate expressions
means bringing a drug into India from a place outside India for its
sale;
(m) “local taxes” means any tax or levy (except excise or import
duty included in retail price) paid or payable to the Government or
the State Government or any local body under any law for the time
being in force by the manufacturer or his agent or dealer;
[((n) "manufacturer" for the purpose of this Order means any
person who manufactures or imports or markets drugs for
distribution or sale in the country; ]*
(o) “market share” means the ratio of domestic sales value (on the
basis of moving annual turnover) of a brand or a generic version of a
medicine and the sum of total domestic sales value of the all brands
and generic versions of that medicine sold in the domestic market
having same strength and dosage form;
(p) “margin to retailer” for the purposes of this Order shall mean
a percentage of price to retailer;
(q) “market based data” means the data of sales related to a drug
collected or obtained by the Government as deemed fit, from time to
time;
(r) “maximum retail price” means the ceiling price or the retail
price plus local taxes and duties as applicable, at which the drug
shall be sold to the ultimate consumer and where such price is
mentioned on the pack;
(s) “moving annual turnover” in a particular month means
cumulative sales value for twelve months in domestic market, where
the sales value of that month is added and the corresponding sales
of the same month in the previous year are subtracted;
(t) “National List of Essential Medicines” means National List of
Essential Medicines, 2011 published by the Ministry of Health and
Family Welfare as updated or revised from time to time and included
in the first schedule of this order by the Government through a
notification in the Official Gazette;
(u) “new drug” for the purposes of this Order shall mean a
formulation launched by an existing manufacturer of a drug of
specified dosages and strengths as listed in the National List of
Essential Medicines by combining the drug with another drug either
listed or not listed in the National List of Essential Medicines or a
formulation launched by changing the strength or dosages or both of
' Substituted vide GSR 1233 (E), w.e.f. 08-05-2015
the same drug of specified dosages and strengths as listed in the
National List of Essential Medicines.
[(v) "non-scheduled formulation" means a formulation, which is
not included in Schedule – 1.]2
(w) “pharmacoeconomics” means a scientific discipline that
compares the therapeutic value of one pharmaceutical drug or drug
therapy to another;
(x) "price list" means a price list referred to in paragraphs 24 and
25 and includes a supplementary price list;
(y) “price to retailer” means the price of a drug at which it is sold
to a retailer which includes duties and does not include local taxes;
(z) "retail price" means the price fixed by the Government for a
new drug under paragraph 5;
(za) "retailer" means a dealer carrying on the retail business of sale
of drugs to customers;
(zb) “scheduled formulation" means any formulation, included in
the First Schedule whether referred to by generic versions or brand
name;
(zc) "schedule" means a Schedule appended to this Order;
(zd) "wholesaler" means a dealer or his agent or a stockist
engaged in the sale of drugs to a retailer, hospital, dispensary,
medical, educational or research institution or any other agency;
(ze) “wholesale price index” means annual wholesale price index
of all commodities as announced by the Department of Industrial
Policy and Promotion, Government of India, from time to time.
(2) All other words and expressions used herein and not defined but
defined in the Act or the Drugs and Cosmetics Act, 1940 (23 of
1940) shall have the meanings respectively assigned to them in the
said Acts.
Previous and next
Questions people ask
Is rule 2 of Drugs (Prices Control) Order, 2013 still in force?
No repeal of Drugs (Prices Control) Order, 2013 is recorded.